Moderna Inc./ US60770K1079 /
6/14/2024 8:55:14 PM | Chg. -5.5800 | Volume | Bid10:00:01 PM | Ask10:00:01 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
130.2600EUR | -4.11% | 193 Turnover: 25,343.9000 |
130.4200Bid Size: 240 | 131.0000Ask Size: 240 | 50.13 bill.EUR | - | - |
GlobeNewswire
6/13
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - ...
GlobeNewswire
6/5
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - ...
GlobeNewswire
5/22
Oruka Therapeutics Expands Leadership Team with Appointment of Industry Veterans Drs. Joseph Senn an...
GlobeNewswire
5/12
TrialWire Patient Recruitment Platform that Reboots Stalled Clinical Trials announced as Multi-Award...
GlobeNewswire
5/8
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
5/8
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Bi...
GlobeNewswire
5/2
Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
5/1
Metagenomi to regain full development rights to its wholly-owned base editing and RIGS systems
GlobeNewswire
4/4
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Aga...
GlobeNewswire
3/4
CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024